Prometheus Laboratories signs collaboration agreement with unnamed partner

Prometheus Laboratories has announced the execution of a research and collaboration agreement with an unnamed pharmaceutical company. The collaboration will use Prometheus’ oncology diagnostic platform (CEER) to develop diagnostic arrays relating to the partner’s oncology pipeline. The CEER arrays may ultimately be used in clinical trials for patient selection and may potentially accelerate the development of novel oncology therapeutic products. Under the terms of the non-exclusive agreement, Prometheus will receive an upfront payment for the development of the first diagnostic array, additional payments for the development of each additional array, and research and development support and testing fees. Further terms of the agreement were not disclosed.